BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36401363)

  • 1. Association of systemic inflammatory and autoimmune manifestations with myelodysplastic syndromes: A systematic review and meta-analysis.
    Liang Q; Zhao J; Zhang L; Gao Z; Pan H; Fang L; Shi J
    Medicine (Baltimore); 2022 Nov; 101(46):e31427. PubMed ID: 36401363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
    Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
    Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
    Zeidan AM; Giri S; DeVeaux M; Ballas SK; Duong VH
    Ann Hematol; 2019 Feb; 98(2):339-350. PubMed ID: 30413901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
    Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
    PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis.
    Yang Y; Tang Z; An T; Zhao L
    Medicine (Baltimore); 2019 Oct; 98(40):e17406. PubMed ID: 31577751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
    Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
    Adrianzen-Herrera D; Sparks AD; Singh R; Alejos-Castillo D; Batra A; Glushakow-Smith S; Pradhan K; Shastri A; Zakai NA
    Blood Adv; 2023 Nov; 7(22):6913-6922. PubMed ID: 37729616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia.
    Byrd JC; Edenfield WJ; Dow NS; Aylesworth C; Dawson N
    Leuk Lymphoma; 1996 Mar; 21(1-2):153-9. PubMed ID: 8907283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of
    Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
    Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
    Braga Lemos M; Rodrigues SR; Schroeder T; Kulasekararaj AG; Matos JE; Tang D
    Eur J Haematol; 2021 Jul; 107(1):3-23. PubMed ID: 33715214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China.
    Wang Y; Huang L; Hua Y; Liu H; Jiang H; Wang H; Zhang W; Fu R; Shao Z
    Hematology; 2021 Dec; 26(1):874-880. PubMed ID: 34753406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
    Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
    Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Ertz-Archambault N; Kosiorek H; Taylor GE; Kelemen K; Dueck A; Castro J; Marino R; Gauthier S; Finn L; Sproat LZ; Palmer J; Mesa RA; Al-Kali A; Foran J; Tibes R
    JAMA Oncol; 2017 Jul; 3(7):936-943. PubMed ID: 28152123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.